| Name | BETd-260 |
| Description | BETd-260, a PROTAC linked by a Cereblon ligand and a BET ligand, has an inhibitory effect on BRD4 protein in leukemic cell lines. |
| In vitro | betd - 260 (ZBC260; Compound 23) induced the degradation of BRD2, BRD3 and BRD4 proteins. BETd-260 acted on RS4; The ic50 measured for 11 leukemic cells was 51 pM. The ic50 of BETd-260 in MOLM-13 cells was 2.2 nM. BETd-260 at 3-10 nM could induce RS4; 11 and MOLM-13 cell apoptosis. Moreover, BETd-260 inhibited the transcription and translation of anti-apoptotic genes Mcl-1, Bcl-2, c-Myc and XIAP and increased the transcription and translation of pro-apoptotic gene Bad in HCC cells[1]. |
| In vivo | BETd-260, administered intravenously at a dosage of 5 mg/kg, effectively degrades the proteins BRD2, BRD3, and BRD4, maintaining this activity for over 24 hours. This process is accompanied by significant PARP and caspase-3 cleavage, along with a marked reduction in c-Myc protein levels in the RS4;11 xenograft mouse model[1]. When administered bi-weekly, three times a week for three weeks, BETd-260 induces rapid tumor regression, achieving a peak regression greater than 90% in RS4;11 xenograft tumor-bearing mice. Notably, this treatment regimen does not lead to weight loss or other toxicity symptoms in the mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 22.5 mg/mL (28.16 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween-80+45% Saline : 0.5 mg/mL (0.63 mM), Sonication is recommended.
H2O : Insoluble, insoluble
|
| Keywords | ZBC-260 | ZBC260 | PROTAC | EpigeneticReaderDomain | Epigenetic Reader Domain | BRD4 | BETd-260 |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Histone Modification Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Inhibitor Library | PPI Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
